ArticleJournal of clinical pharmacy and therapeutics2022

Incidence and risk factors for hyperkalaemia in patients treated for COVID-19 with nafamostat mesylate.

Kentaro Kodama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.